Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors.
Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells.
Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). It also develops JTX-1484 and JTX-2134 product candidates..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 2.0M |
| Three Month Average Volume | 62.4M |
| High Low | |
| Fifty-Two Week High | 5.87 USD |
| Fifty-Two Week Low | 0.5773 USD |
| Fifty-Two Week High Date | 06 May 2022 |
| Fifty-Two Week Low Date | 13 Dec 2022 |
| Price and Volume | |
| Current Price | 1.88 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 0.54% |
| Thirteen Week Relative Price Change | 59.91% |
| Twenty-Six Week Relative Price Change | -18.00% |
| Fifty-Two Week Relative Price Change | -61.87% |
| Year-to-Date Relative Price Change | 60.12% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | 55.37% |
| Twenty-Six Week Price Change | -10.48% |
| Five Day Price Change | -2.84% |
| Fifty-Two Week Price Change | -63.98% |
| Year-to-Date Price Change | 69.37% |
| Month-to-Date Price Change | -2.59% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.54223 USD |
| Book Value Per Share (Most Recent Quarter) | 3.54223 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.54223 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 3.54223 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.97057 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.58681 USD |
| Revenue Per Share (Trailing Twelve Months) | 1.58681 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.98535 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.98599 USD |
| Normalized (Last Fiscal Year) | -0.98535 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.98535 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.98599 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.98535 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.98599 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.66662 USD |
| Cash Per Share (Most Recent Quarter) | 3.66662 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.94471 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.94496 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.57659 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -62 |
| Cash Flow Revenue (Trailing Twelve Months) | -36 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -61.93% |
| Pretax Margin (Last Fiscal Year) | -61.93% |
| Pretax Margin (5 Year) | -40.57% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -63.71% |
| Operating Margin (Trailing Twelve Months) | -63.71% |
| Operating Margin (5 Year) | -43.43% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -62.10% |
| Net Profit Margin (Trailing Twelve Months) | -62.10% |
| Net Profit Margin (5 Year) | -40.64% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -7.33% |
| Tangible Book Value (5 Year) | 1.85% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | 2.74% |
| Revenue Change (Trailing Twelve Months) | 204.75% |
| Revenue Per Share Growth | -7.82% |
| Revenue Growth (5 Year) | -17.84% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -42.87% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 267.14% |
| EPS Change (Trailing Twelve Months) | 46.20% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -189,542,000 |
| Net Debt (Last Fiscal Year) | -189,542,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | 1 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 11 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 1 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 8 |
| Current Ratio (Most Recent Quarter) | 8 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -29,796,000 |
| Free Cash Flow (Trailing Twelve Months) | -29,796,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -21.89% |
| Return on Assets (Trailing Twelve Months) | -21.89% |
| Return on Assets (5 Year) | -13.33% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -25.03% |
| Return on Equity (Trailing Twelve Months) | -25.03% |
| Return on Equity (5 Year) | -17.57% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -24.09% |
| Return on Investment (Trailing Twelve Months) | -24.09% |
| Return on Investment (5 Year) | -15.45% |